Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 70 clinical trials
Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer

This phase II trial studies how well avelumab with or without cetuximab work in treating patients with skin squamous cell cancer that has spread to other places in the body. Immunotherapy with

pd-l1
measurable disease
cetuximab
neutrophil count
investigational drug
  • 30 views
  • 06 Apr, 2022
  • 372 locations
Sentinel Lymph Node Biopsy for Cutaneous Squamous Cell Carcinoma of the Head and Neck

Current guidelines in management of regional lymph node metastases for cSCC patients include surgical resection with or without adjuvant therapy as well as chemotherapy and interdisciplinary management; in advanced disease, supportive and palliative care is recommended. These guidelines also define the role of SLNB in management of high-risk cSCC as …

  • 0 views
  • 21 Apr, 2022
  • 1 location
Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers

In this clinical phase I, non-randomized, open-label, uncontrolled, interventional, multi-center trial, 20 adult subjects (≥ 18 years of age) with advanced non-melanoma skin cancers will receive a fixed dose of 0.1 mg of IFx-Hu2.0 intralesionally as monotherapy in up to three lesions at up to three time points. Subjects will …

hysterectomy
tubal ligation
squamous cell carcinoma
metastasis
measurable disease
  • 2 views
  • 21 Apr, 2022
  • 4 locations
Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)

This phase II single-arm two-stage neoadjuvant study of pembrolizumab in patients with PD-1 naïve high-risk resectable cutaneous squamous cell carcinoma (cSCC) will be conducted over a 52-week

measurable disease
squamous cell carcinoma
ulceration
metastasis
pembrolizumab
  • 0 views
  • 09 Jul, 2022
  • 1 location
High-Risk Skin Cancers With Atezolizumab Plus NT-I7

-risk melanoma, Merkel Cell Carcinoma (MCC) and cutaneous Squamous Cell Carcinoma (cSCC)

pd-l1
squamous cell carcinoma
ipilimumab
braf inhibitor
systemic therapy
  • 14 views
  • 26 Feb, 2022
  • 7 locations
Exercise to Boost Response to Checkpoint Blockade Immunotherapy

30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles

ipilimumab
nivolumab
immunomodulator
immunologic adjuvant
pembrolizumab
  • 0 views
  • 23 May, 2022
  • 1 location
Study of Metabolic Changes in the Transformation Malignant Precancerous Skin Lesions (MITOSKIN)

Skin carcinomas are the most frequent cancers in the world, including basal cell carcinomas and cutaneous squamous cell carcinoma (cSCCs), with more than 60.000 new annual cases in France. Their

squamous cell carcinoma
actinic keratosis
skin lesions
skin lesion
metastasis
  • 0 views
  • 24 May, 2022
  • 1 location
  • 0 views
  • 22 Mar, 2022
  • 7 locations
RM-1995 Photoimmunotherapy, as Monotherapy or Combined With Pembrolizumab, in Patients With Advanced CuSCC and HNSCC

photoimmunotherapy treatment as monotherapy (phase 1a) or combined with pembrolizumab (phase 1b) in patients with cutaneous squamous cell carcinoma (cuSCC) or head and neck squamous cell carcinoma (HNSCC) that has

  • 0 views
  • 21 Apr, 2022
  • 1 location
Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site

This phase II trial tests whether atezolizumab works to shrink tumors before surgery in patients with head and neck squamous cell cancer with an unknown or historic primary site that has spread to other places in the lymph nodes (regionally metastatic). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help …

  • 0 views
  • 24 Mar, 2022
  • 1 location